Summary

US Neuroblastoma Drugs Market is valued approximately USD 172 million in 2023 and is anticipated to grow with a healthy growth rate of more than 7.11% over the forecast period 2024-2032. Neuroblastoma is a cancer primarily occurring in young children under five years old, originating in nerve tissue specifically in the adrenal glands atop the kidneys. It emerges from immature nerve cells, called neuroblasts, known for its diverse symptoms and outcomes. These range from abdominal lumps, altered bowel patterns, bone discomfort, fatigue, to skin alterations, showcasing its varied presentation. Neuroblastoma drugs are medications tailored to combat neuroblastoma. It encompasses chemotherapy agents like cisplatin and etoposide, targeted therapies such as crizotinib targeting the ALK gene, immunotherapies like dinutuximab, differentiation agents like retinoic acid, and radiopharmaceuticals like I-131 MIBG. Treatment plans are individualized based on factors like the cancer stage and patient's health involving a combination of therapies designed by a team of specialists to optimize effectiveness. The rise in expansion of immunotherapy options for neuroblastoma treatment is a key trend for the US Neuroblastoma Drugs Market. Clinical studies are being conducted to investigate the efficacy of immunotherapeutic medications, such as immune checkpoint inhibitors and monoclonal antibodies, in stimulating the body's own immune system to target and eliminate cancer cells. Those with high-risk or relapsed neuroblastoma have a new prospect because of these cutting-edge immunotherapy techniques.

Furthermore, continuous research efforts have resulted in an enhanced comprehension of the molecular and genetic underpinnings of neuroblastoma. This understanding has paved the way for the creation of targeted drug therapies, consequently augmenting the size of the neuroblastoma drugs market. For instance, in 2023, Y-mAbs Therapeutics sponsored a clinical study investigating Naxitamab's efficacy among high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow, as indicated on ClinicalTrials.gov. Moreover, the region benefits from the significant presence of key industry players that are actively engaged in strategic initiatives like product approvals and partnerships, contributing significantly to market expansion in the region. However, adverse side effects associated with neuroblastoma drugs and stringent regulatory requirement for drug approvals are expected to stifle US Neuroblastoma Drugs Market growth between 2022 and 2032.


Major market player included in this report are:
Eli Lilly and Company
Bristol-Myers Squibb Company
Y-mabs Therapeutics, Inc.
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10



The detailed segments and sub-segment of the market are explained below:

By Type
Chemotherapy
Immunotherapy
Others

By Route of Administration
Oral
Injectable

By Distribution Channel
Online
Offline

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Chapter 1. US Neuroblastoma Drugs Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. US Neuroblastoma Drugs Market Size & Forecast (2022- 2032)
2.2. Segmental Summary
2.2.1. By Type
2.2.2. By Route of Administration
2.2.3. By Distribution Channel
2.3. Key Trends
2.4. Recession Impact
2.5. Analyst Recommendation & Conclusion
Chapter 3. US Neuroblastoma Drugs Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. US Neuroblastoma Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. US Neuroblastoma Drugs Market Size & Forecasts by Type 2022-2032
5.1. Chemotherapy
5.2. Immunotherapy
5.3. Others
Chapter 6. US Neuroblastoma Drugs Market Size & Forecasts by Route of Administration 2022-2032
6.1. Oral
6.2. Injectable
Chapter 7. US Neuroblastoma Drugs Market Size & Forecasts by Distribution Channel 2022-2032
7.1. Online
7.2. Offline
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.1.1. Company 1
8.1.2. Company 2
8.1.3. Company 3
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Eli Lilly and Company
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Bristol-Myers Squibb Company
8.3.3. Y-mabs Therapeutics, Inc.
8.3.4. Company 4
8.3.5. Company 5
8.3.6. Company 6
8.3.7. Company 7
8.3.8. Company 8
8.3.9. Company 9
8.3.10. Company 10
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes